This is the first study to show that the repeat genome can be effectively targeted using CRISPR technology, the first use of CRISPR inhibition for a human disease, and the first use of CRISPR technology in primary human muscle cells.
High - resolution maps of enhancer - promoter interactions in rare primaryhuman T cell subsets and coronary artery smooth muscle cells link variants associated with autoimmune and cardiovascular diseases to target genes.